Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
European Urology|November 9, 2019
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancerAlfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2022
Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitorsMaud Velev, Barouyr Baroudjian, Roxane Pruvost, et al.
Nature Communications|October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
Clinical Genitourinary Cancer|December 29, 2019
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor GroupMarine Sroussi, Reza Elaidi, Aude Fléchon, et al.
European Urology Oncology|March 4, 2024
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate CancerLudovic Bigot, Jonathan Sabio, Loic Poiraudeau, et al.
NPJ Precision Oncology|September 23, 2020
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave RoussyGonzalo Recondo, Linda Mahjoubi, Aline Maillard, et al.
Clinical Genitourinary Cancer|June 1, 2023
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 TrialValentina Orlando, Damien Drubay, Pernelle Lavaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway InhibitorsNaoual Menssouri, Loïc Poiraudeau, Carole Helissey, et al.
European Urology|October 28, 2017
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 TrialPernelle Lavaud, Gwenaëlle Gravis, Stéphanie Foulon, et al.
JAMA Network Open|October 28, 2020
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene AberrationsSabine Schmid, Aurelius Omlin, Celestia Higano, et al.
Pageof 6